Acanthamoeba Keratitis (AK) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acanthamoeba keratitis (AK) is a rare cornea infection that is difficult to diagnose and treat properly. It can be a sight-threatening disease. Acanthamoeba is currently divided into twenty-two different genotypes (T1–T22) based on 18s rRNA gene typing. Based on genotype variations, clinical presentation and response to therapy vary. The pathogen is transmitted through corneal contact with a contaminated substance. Most cases seen in humans seem to be associated with contaminated water, soil, or trauma to the eye. The progression of Acanthamoeba keratitis occurs in two main phases. An initial phase where infiltration is limited to the corneal epithelium, and a second phase where the parasite invades the underlying stroma. Once in the stroma, extensive damage to the collagen matrix occurs, which provokes intense inflammation.
·
The estimated incidence of Acanthamoeba
keratitis (AK) cases with soft contact lens wearers ranges between 4.5 to 7.8
cases per 100,000 population.
Thelansis’s “Acanthamoeba Keratitis
(AK) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acanthamoeba
Keratitis (AK) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acanthamoeba Keratitis (AK) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Acanthamoeba Keratitis (AK) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment